SKYE has been in the news 328% more than usual
Jan 07, 2026, 1:32 AM
-0.49%
What does SKYE do
Skye Bioscience, a San Diego-based biopharmaceutical company, focuses on cannabinoid-based therapeutics for metabolic disorders and inflammation. Its Phase 2 candidates include nimacimab for obesity and SBI-100 OE for glaucoma.
SKYE has been in the news recently: Skye Bioscience has partnered with Halozyme Therapeutics to develop a higher-dose version of nimacimab for obesity, with plans for a Phase 2b trial in mid-2026. Additionally, shareholders who purchased Skye Bioscience stock between November 4, 2024, and October 3, 2025, are being invited to participate in a class action lawsuit by a January 16, 2026 deadline.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.